^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD19 (CD19 Molecule)

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    2d
    CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy. (PubMed, NPJ Precis Oncol)
    CD22-targeted therapies, including CD22 CAR-T cells and Inotuzumab Ozogamicin, show promise as alternatives, although data in those patients is limited...Among these patients, 27.9% received blinatumomab, 58.1% received CD19 CAR-T cells, and 14% received both...Patients with extramedullary disease had worse remission rates, and those previously resistant to CD19-targeted therapy had shorter RFS. CD22-targeted therapies offer a potential option for patients progressing after CD19-targeted immunotherapy, but high relapse rates highlight the need for better strategies for lasting remission.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • anti-CD22 CAR-T cell therapy
    4d
    Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma. (PubMed, J Med Cases)
    CD19 expression may be diminished by exams using a tafasitamab-competitive-binding clone. This case highlights not only the concern of HBV reactivation, but also the diagnostic challenge due to CD19 epitope masking following tafasitamab therapy.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    lenalidomide • Monjuvi (tafasitamab-cxix)
    4d
    CHT105 for the Treatment of Refractory Lupus Nephritis (clinicaltrials.gov)
    P=N/A, N=14, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New trial
    |
    JAK2 (Janus kinase 2) • CD19 (CD19 Molecule) • JAK1 (Janus Kinase 1) • TYK2 (Tyrosine Kinase 2)
    |
    cyclophosphamide • fludarabine IV
    5d
    ECLAT: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Memorial Sloan Kettering Cancer Center | N=27 --> 0 | Trial completion date: Aug 2028 --> Mar 2026 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Mar 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD4 (CD4 Molecule)
    |
    lenalidomide • Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    10d
    Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Shenzhen University General Hospital
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV
    12d
    Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)
    The 11q23 rearrangement ALL with non-KMT2A::AFF1 transcript is mainly KMT2A::MLLT1, T-ALL is more common, and the rate of chromosomal karyotype detection is relatively low. Persistent positive KMT2A-r is unfavorable for patient survival, and allo-HSCT during the CR1 period may improve patient survival.
    Retrospective data • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • WT1 (WT1 Transcription Factor) • CD22 (CD22 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CD2 (CD2 Molecule) • AFDN (Afadin, Adherens Junction Formation Factor) • FUT4 (Fucosyltransferase 4) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    KMT2A rearrangement
    12d
    A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Sheba Medical Center
    New P1/2 trial
    |
    TP53 (Tumor protein P53) • CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    13d
    A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P2, N=222, Recruiting, National Cancer Institute (NCI) | Phase classification: P3 --> P2
    Phase classification
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)
    |
    TruSight RNA Pan-Cancer Panel
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
    13d
    NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) (clinicaltrials.gov)
    P2/3, N=40, Recruiting, Health Institutes of Turkey
    New P2/3 trial
    |
    CD19 (CD19 Molecule) • CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    14d
    FIL_COLUMN: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cytarabine • bendamustine • Zynlonta (loncastuximab tesirine-lpyl)
    18d
    MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, King Hussein Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 (CD19 Molecule)
    |
    zorpocabtagene autoleucel (MB-CART 19.1)